

Englumafusp alfa

Cat. No.:	HY-P990017
Target:	CD19
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Englumafusp alfa (CD19-4-1BBL; R07227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells^[1].

REFERENCES

- [1]. Antonio Tapia-Galisteo, et al. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. *J Hematol Oncol.* 2023 Jul 27;16(1):83.
- [2]. George Fromm, et al. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. *Front Immunol.* 2023 Sep 19;14:1236332.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA